What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug
The sale of experimental weight-loss drug retatrutide has made its way from online vendors to brick-and-mortar stores in New York City, raising concerns among medical experts and regulators. In a recent investigation by CBS News, it was found that bodegas in Brooklyn are openly selling a version of retatrutide labeled as “not for human consumption” for $95, with no age verification or prescription required.
The vial purchased from one of these stores is from a peptide vendor called Indr Labs, which claims its products are for research use only. However, the lab reports on their website, which are meant to show the purity and makeup of the peptides, have raised questions. For example, the certificate for retatrutide appears to show a different weight-loss drug, tirzepatide, and indicates analysis by a laboratory called Vanguard Laboratory, which has denied issuing these reports.
Despite these irregularities, Indr Labs did not respond to inquiries and instead changed its website to require a password for access to lab reports. Efforts to reach the owner of the store where the purchase was made were unsuccessful. The FDA, which has warned against buying research-grade retatrutide due to potential health risks, did not respond to requests for comment.
Eli Lilly, the pharmaceutical company developing retatrutide for obesity and type 2 diabetes, has called on regulators and law enforcement to crack down on the illicit sale of black-market drugs like retatrutide. Clinical trials have shown that retatrutide could be more effective than FDA-approved weight-loss drugs, sparking interest and demand for the drug even before FDA approval.
Despite the FDA’s role in determining drug safety and effectiveness, it has struggled to regulate the sale of retatrutide, allowing it to proliferate in both online and physical retail settings. As the demand for experimental weight-loss drugs like retatrutide continues to grow, there is a pressing need for stricter regulation and oversight to protect consumers from potential harm. The Food and Drug Administration (FDA) has taken enforcement action against companies that claim retatrutide is for research purposes but advertise its supposed health benefits. One such company, Indr Labs, promotes its peptides as having “98% purity” and offers “discreet packaging” on its website. However, the company explicitly states that the product is only for research use and requires online purchasers to acknowledge this disclaimer. Despite this, a storefront owned by Mr. Green was found to be advertising human-sounding benefits of retatrutide such as “cardiometabolic health” and “weight management.”
This aggressive marketing tactic is not unique to Indr Labs. Just a couple of blocks away, Classy Bite Deli 2 was also found to be selling retatrutide with the same Indr Labs poster displayed in its window. Efforts to reach the deli’s owner for comment were unsuccessful. Jeff Cohen, a lawyer and co-founder of the American Peptide Association, described the practice of advertising research-grade retatrutide in a retail setting as “incredibly aggressive.” He likened selling research-use peptides to driving on an interstate, where most people do not abide by the rules but only the outliers get caught.
While many individuals and even some medical professionals claim to have experienced positive results from retatrutide, there are also reports of concerning side effects. The American Poison Centers has noted a significant increase in reports of toxicities associated with the drug, and the FDA is receiving more claims of adverse events, though these remain unverified. In a recent case, a 72-year-old woman reported “severe skin irritation” and ongoing medical issues after being prescribed retatrutide. She only learned from a CBS News investigation that the drug is not FDA approved.
It is crucial for consumers to be aware of the risks associated with purchasing and using products like retatrutide, especially when they are marketed for purposes beyond their intended use. The FDA continues to monitor and take action against companies that make misleading claims about the health benefits of research-grade peptides. It is essential for individuals to consult with healthcare professionals before using such products to ensure their safety and well-being.
